Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy

Activated androgen receptor binds to androgen-responsive elements (AREs) in genome to regulate target gene transcription and, consequently, mediates physiological or tumorigenic processes of the prostate. Our aim was to determine whether genetic variants in AREs are associated with clinical outcomes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2012-03, Vol.23 (3), p.707-713
Hauptverfasser:	Huang, C.-N., Huang, S.-P., Pao, J.-B., Chang, T.-Y., Lan, Y.-H., Lu, T.-L., Lee, H.-Z., Juang, S.-H., Wu, P.-P., Pu, Y.-S., Hsieh, C.-J., Bao, B.-Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androgen Antagonists - therapeutic use androgen-deprivation therapy androgen-responsive element Antineoplastic agents Arrestins - genetics Biological and medical sciences Genotype Gynecology. Andrology. Obstetrics Humans Kaplan-Meier Estimate Male Male genital diseases Medical sciences Neoplasm Staging Nephrology. Urinary tract diseases Pharmacology. Drug treatments Phosphoproteins - genetics Polymorphism, Single Nucleotide Prognosis Proportional Hazards Models prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - mortality Receptors, Androgen - genetics Response Elements - genetics single-nucleotide polymorphism Tumors Tumors of the urinary system Urinary tract. Prostate gland Vascular Endothelial Growth Factor Receptor-1 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!